Ista Presents Results From Xibrom Studies

Ista Pharmaceuticals reported results from two Phase III trials of once-daily Xibrom, a new formulation of the company’s ocular nonsteroidal anti-inflammatory agent.

The multicenter studies evaluated Xibrom (bromfenac sodium ophthalmic solution) versus placebo in more than 500 patients who underwent cataract surgery. The findings demonstrated Xibrom was superior to placebo in achieving both the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery and the secondary efficacy endpoint of elimination of ocular pain at day one, Ista said.

The drug also produced a lower incidence of ocular adverse events compared with placebo.